Stada Arzneimittel Generics Company Intelligence Report

Date: January 22, 2011
Pages: 16
Price:
US$ 340.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SF538F8D256EN
Leaflet:

Download PDF Leaflet

Stada Arzneimittel Generics Company Intelligence Report
Stada Arzneimittel is one of the two major independent German generic manufacturers, along with ratiopharm. However, with Teva's recently-announced acquisition of ratiopharm, Stada will soon be the only major independent generic manufacturer in Germany.

Sales in 2005 broke the one billion euro barrier for the first time; in 2008, sales reached 1,646.2 million euros, but dipped in 2009 to 1,568.8 million euros (US$2,187.9 million). However, net income rose by 31.8% to 100.4 million euros (US$140.0 million).

Unbranded generics accounted for around 71.2% of sales, with the bulk of the remainder being branded generic products. Stada operates two core segments: Generics and Branded Products.

Stada is a Euro-centric firm. Sales in Europe accounted 1,501.0 million euros (US$2,093.3 million) or around 96% of Stada’s sales in 2009, with sales in Germany accounting for around 34%.

The USA is not an important market for Stada at the moment. In July 2006, the company announced the sale of its US business to DAVA, effectively exiting the market.

Stada is working on a number of biosimilar products, through an agreement with Bioceuticals Arzneimittel AG
EXECUTIVE SUMMARY

INTRODUCTION

Build the future
PRODUCTS

Stada Arzneimittel: top five API sales in 2009, in euro millions and US$ millions
Stada Arzneimittel: number of product launches per year
Biosimilars

FINANCIAL RESULTS

Latest Interim Results, First Nine Months of 2010
Stada Arzneimittel: nine month results, in euro 000s and US$000s
Stada Arzneimittel: quarterly results, in euro 000s
Stada Arzneimittel: quarterly results, in US$000s
Stada Arzneimittel: selected regional nine month results, in euro 000s and US$000s
Stada Arzneimittel: selected regional quarterly results, in euro 000s
Stada Arzneimittel: selected regional quarterly results, in US$000s
Latest Fiscal Year Results, FY09
Stada Arzneimittel: fiscal year results, in euro millions
Stada Arzneimittel: fiscal year results, in US$ millions
Segment Data
Stada Arzneimittel: fiscal year results by segment, in euro millions
Stada Arzneimittel: fiscal year results by segment in US$ millions
Geographic Segment Data
Germany
Russia
Belgium
Serbia
Italy
France
Spain
United Kingdom
Stada Arzneimittel: selected geographic segment data, in euros millions
Stada Arzneimittel: selected geographic segment data, in US$ millions

MAJOR DEVELOPMENTS

Litigation
Stada says olanzapine judgement will cost the firm

CONTACT DETAILS
5
Skip to top


Ranbaxy Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 24 pages
Apotex Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 20 pages
Hospira Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 18 pages
Krka Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 16 pages

Ask Your Question

Stada Arzneimittel Generics Company Intelligence Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: